Related references
Note: Only part of the references are listed.Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients
G. Lefevre et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Rivastigmine exposure provided by a transdermal patch versus capsules
Francois Mercier et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease -: rivastigmine patch versus capsule
Bengt Winblad et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2007)
Absorption of rivastigmine from different regions of the gastrointestinal tract in humans
L Lee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry
F Pommier et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2003)
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months
T Darreh-Shori et al.
NEUROLOGY (2002)
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
MW Jann et al.
CLINICAL PHARMACOKINETICS (2002)
Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type
M Hossain et al.
CLINICAL PHARMACOKINETICS (2002)
Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit
E Giacobini et al.
JOURNAL OF NEURAL TRANSMISSION (2002)
Practice parameter: Management of dementia (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology
RS Doody et al.
NEUROLOGY (2001)
Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease
BP Imbimbo
CNS DRUGS (2001)
Confidence interval criteria for assessment of dose proportionality
BP Smith et al.
PHARMACEUTICAL RESEARCH (2000)
β-amyloid1-42 binds to α7 nicotinic acetylcholine receptor with high affinity -: Implications for Alzheimer's disease pathology
HY Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease
MW Jann
PHARMACOTHERAPY (2000)
Share Paper
